DEBx Medical, an Amsterdam-based innovative leader in advanced wound care, announces the successful completion of its second round of investment, led by TVM Capital Healthcare . The funding will accelerate DEBx Medical’s global expansion into key markets around the world.

The investment follows a successful seed round of funding and reflects growing confidence in DEBx Medical’s innovative approach to treating chronic wounds, particularly through its breakthrough solution, DEBRICHEM ^® , a topical desiccant agent used to eradicate biofilm and infection from chronic wounds.

Global market expansion will transform chronic wound care

This second round of investment will support the company's strategy to expand into highly regulated and competitive markets, further strengthening DEBx Medical's mission to transform chronic wound care and improve patient outcomes.

Chronic wounds impose a considerable burden on healthcare systems worldwide, not only due to their frequency but also due to associated costs, complications and impacts on patients' quality of life.

DEBRICHEM ^® offers an unparalleled solution, completely eradicating biofilm and infection from chronic wounds. With CE and ISO certifications, the company has successfully treated thousands of patients since its introduction to the market.

Investor perspective

“This new round of funding from TVM Capital Healthcare will accelerate the commercialization of DEBRICHEM® ^globally and enable DEBx Medical to reach more patients and alleviate the suffering caused by non-healing wounds,” commented Tristan de Boysson , Managing Partner of TVM Capital Healthcare. “We are also reaffirming our commitment to the TVM Healthcare Afiyah Fund’s strategy to bring innovative solutions to the MENA region, particularly the Kingdom of Saudi Arabia, and we look forward to working with this impressive team to achieve these goals.”

The renewed investment from TVM Capital Healthcare will further enable DEBx Medical to expand its commercialization initiatives.

"We are excited to take this important step in DEBx Medical's journey toward global expansion," said Bert Quint , CEO of DEBx Medical. "This round of financing will allow us to enter key global markets where the impact of chronic wounds is still significant. The support from our investors is a strong validation of our product's potential to transform wound care practices around the world. "

Driving innovation in wound care

DEBRICHEM® has ^already made a significant impact in Europe and parts of the MENA region, including Saudi Arabia, offering healthcare professionals a powerful solution to treat chronic wounds. The product has shown remarkable results in helping to restart the healing process in wounds where biofilm and infection were a barrier.

A media excerpt accompanying this announcement is available by clicking this link .

Future growth and development

In addition to expanding its geographic reach, DEBx Medical plans to continue advancing its research and development efforts to introduce new wound care solutions. The company’s focus on clinical data and evidence-based medicine will continue to be a key driver as it seeks to expand its product portfolio and address unmet needs in chronic wound care.

About DEBx Medical

DEBx Medical is dedicated to transforming wound care through innovative, science-based solutions. Founded in 2019, the company’s mission is to improve the lives of patients with chronic wounds by providing healthcare professionals with revolutionary tools to effectively treat complex wounds. The company’s flagship product, DEBRICHEM ® , is a topical dissecting agent that eliminates biofilm and infection, promoting faster, more efficient wound healing. For more information, visit: DEBx Medical - Innovating The Future of Wound Care (debx-medical.com)

About TVM Capital Healthcare

TVM Capital Healthcare is a global private equity firm specializing in healthcare with a focus on emerging markets. Headquartered in Dubai and Singapore, with offices in Riyadh, Boston, Munich and Ho Chi Minh City, the firm invests expansion and growth capital in healthcare companies to improve local access to quality, affordable care and local sourcing of medical products across the pharmaceutical, medical device and diagnostics sectors. The investment and operating partners, as well as a robust group of regional and international senior advisors, have long track records of successful healthcare investments and extensive operating experience in the Middle East and Southeast Asia. For more information, visit: TVMCapitalHealthcare.com 

For social communication, please contact:

DEBx Medical: Chandrita Jaisinghani, press@debx-medical.com, +31 85 0878096

Source: globenewswire.com

Report Abuse